FeesSafety
Pluang+

Amneal Pharmaceuticals' strong Q3 and pipeline boost buy rating despite risks.

Company Fundamentals
17 Nov 2026, 17:38 WIB
Seeking Alpha
View Source
Bullish
Amneal Pharmaceuticals' strong Q3 and pipeline boost buy rating despite risks.

Amneal Pharmaceuticals reported a fourth consecutive earnings beat with Q3 revenue up 10%, leading to higher revenue guidance for fiscal year 2026. The company's growth prospects are supported by its robust drug pipeline, niche market demand, and integration of Kashiv, which is expected to generate $400-$500 million in synergies. While valuation is modest and projected upside exceeds 10%, risks include elevated debt, integration challenges, and sector-specific issues like drug approvals and supply chain disruptions. Overall, positive operating cash flow and improving margins support the quality of earnings, making the stock attractive despite some risks.

Amneal Pharmaceuticals holds a market capitalization of $7.40 billion and an enterprise value of $10.52 billion as of November 17, 2026, 22:52 WIB. Despite the positive earnings momentum and growth prospects highlighted in the news, the stock price on Pluang is down 1.74% at USD 20.86, with a trading volume of 1,676,531 shares. The typical hold time for AMRX on Pluang is 19 days, indicating moderate investor engagement.

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App